1979 results about "Use medication" patented technology

Devices and methods to heat and cool human beings, including inducing and maintaining hypothermia in human patients. Methods include inducing hypothermia to treat ischemic events, including heart attack and stroke, to limit damage caused by the ischemic event. Methods can include: using the lungs for heat exchange; using cooled gases for ventilation; using helium in the ventilation gas mixture, using medications to control reflex heat production; and injecting a perfluorocarbon mist into the gas stream to increase the cooling rate. The high thermal conductivity and diffusivity of helium results in greater inspired gas temperature equalization toward body temperature. Due to the latent heat of vaporization, addition of even small quantity of phase-change perfluorocarbon dramatically increases the heat carrying capacity of the respiratory gases. Hypothermia may be terminated by discontinuing the medications and warming the patient using a warmed helium-oxygen mixture.

The invention discloses a clinical medication decision support system which relates to the field of medical systems. The system comprises a standard treatment medication module, a medication safety reviewing module and a prescription monitoring and warning module, wherein the standard treatment medication module is used for providing diagnosis and treatment reference information and a medication reference scheme according to pathology and physiology information of a patient, so that a doctor can make a prescription; the medication safety reviewing module is used for reviewing the medication safety condition of the patient according to the prescription and generating a reviewing log; and the prescription monitoring and warning module is used for estimating the prescription and generating warning information according to the reviewing log. The system can automatically provide the medication scheme according to the pathology and physiology information of the patient, assist in the doctor to make the prescription, review the safety of the prescription, estimate the prescription and conduct warning on the reviewing result, thus remarkably improving the security, normalization and standardization of clinical medication; and furthermore, by virtue of an antibacterial agent management module, the effective management and monitoring on antibacterial agents are realized, and thus the safety of the clinical medication is further improved.

Devices and systems for controlling the dispensing of medication and methods for using the devices and systems are provided. The system can include a dispenser device capable of holding and delivering at least one medication. A controller can be operatively connected to the dispenser. The controller can automatically operate the dispenser for movement to a dispensing position at a predetermined time. An electronic communication device for connecting the system to a remote facility can be provided. An identification verification device for restricting access to the system can be in communication with the controller of the system. A location determination device for determining the location of the system can also be provided.

The present invention discloses a slowly-released oral medicine preparation which is made up by using breviscapine as main raw material and has the functions of promoting blood circulation and removing blood stasis, removing obstruction in the channels to relieve pain for curing angiocardiopathy and cerebrovascular disease with obvious therapeutic effect and its preparation method. Said slowly-released tablet (by one tablet) contains 60-120 mg of breviscapine, 20-75 mg of diluent, 50-150 mg of filling agent and 10-50 mg of slow release material. Said invention also provides its preparation method and concrete steps.

The invention provides a method, a system and equipment for intelligent medication guidance. The method comprises the following steps of establishing a multi-dimensional attribute item dictionary related with the medication guidance, extracting the medication guidance contents and relevant element information of the medication information, utilizing the elements of the multi-dimensional attribute item dictionary to process each medication relevant information, and generating a medication guidance and relevant element database; according to the medication guidance contents and the importance levels of disease therapy and medicine adverse effects when different patients and different diseases use different medicines, setting the priority of each medication guidance information under different use conditions; finally, intelligently matching and comparing the relevant medication information of the patient and the medication guidance and relevant element database, sequencing the extracted medication guidance information, and generating the list of the patient medication guidance information. The method, the system and the equipment for the intelligent medication guidance have the advantage that the medication guidance can be provided for the patient by the informationizing technique and equipment.

The invention discloses an injection-purpose medicine composition for improving stability of ligustrazine medicine injection formulation and a preparation method of the injection-purpose medicine composition. The injection-purpose medicine composition is prepared by the method comprising following steps: dissolving ligustrazine salt in water for injection, adjusting the pH value of the liquid medicine by adding citric acid and / or sodium citrate used as a pH regulator, wherein the dosage of the citric acid and / or sodium citrate ranges from (0.1mg to 200.0mg) / 100ml. In the invention, pH value of the injection liquid can be more stable, the content of ligustrazine degradation substance is greatly reduced compared with that of the prior art, the clarity of the ligustrazine injection liquid is improved under the condition of not using other cosolvents to increase the clinical application risk, particularly, the problems of small white spots, white blocks and solution turbidity are solved under the condition that the ligustrazine injection liquid is stored for a long time by adopting the prior art, and the medicine composition ensures that the inspection of visible foreign substances of the product is in accordance to the formulation of medicine quality standard, and is convenient for clinical medication and popularization.

The invention belongs to a clinical administration management system, in particular to a clinical safe and rational administration decision support system. The system at least comprises the following modules: a clinical rational administration specification module, a safe administration checking module, a medical care administration prompt and non-medical care medicament use management module, a rational administration supervision module, a hospital infection supervision module and an information island module, wherein the clinical rational administration specification module is used for storing administration standards of clinical common diseases and high-incidence diseases, the administration standards are acquired by comparing, discriminating and counting the known clinical common diseases and high-incidence diseases, and when the pathological information of a patient is input into a doctor's advice decision unit through input equipment, the doctor's advice decision unit compares the pathological information of the patient with pathological information of the clinical common diseases and high-incidence diseases. The invention provides a clinical safe and rational administration decision support system, which can rapidly, economically and effectively supervise disordered, trial and experiential clinical administration.

The oral cavity quick dissolving and quick disintegrating freeze dried tablet for children includes at least one medicinal active component and at least one medicinal stuffing, adhesive and other supplementary material. It is loose and porous tablet in network structure and prepared through common freeze drying process. The said medicinal active component may be different children's medicines, such as antibiotic, antipyretic, analgesic, cough stopping and phlegm eliminating medicine, cold medicine, etc. Bitter or excitant medicine may be coated and water insoluble medicine is prepared intofine powder of 50 micron below size for stable dispersion in liquid. The present invention has fast disintegration, no jamming in throat, simple preparation process and low cost.

The invention discloses a prescription auditing method and a system thereof, wherein the method comprises the steps of extracting medicine taking characteristic information of a patient, and identifying prescription information; according to the medicine taking characteristic information and a pre-trained medicine taking recommending model, obtaining recommending medicine information; and performing rationality auditing on a medicine taking doctor's advice in the prescription information according to the recommending medicine information, the medicine taking characteristic information, a preset expert rule database and a medical body knowledge database. The prescription auditing method and the system thereof have advantages of assisting a prescription pharmacist and a doctor for realizinghigher scientific performance and higher rationality in medicine taking, reducing medical cost of the patient and sanitation resource wastage, realizing in-time finding of the unreasonable medicine taking condition, and maximally alleviating and even settling a medicine abuse problem.

The invention provides a medicine taking reminder, a mobile terminal provided with the medicine taking reminder, and a medicine taking reminding method. The medicine taking reminder comprises an information reading unit, an information processing unit and a reminding unit, wherein the information reading unit can obtain the information identification code of drug; the information processing unit can obtain drug information data as per the information identification code of drug and generates the medicine taking reminding data as per the drug information data; and the reminding unit can perform reminding operate as per the medicine taking reminding data. The medicine taking reminder can obtain the medicine taking reminding data corresponding to the identification code conveniently, avoids the trouble that a user needs to set the time and reminding content of an alarm clock manually every time, and reduces the operation difficulty effectively; individual reminding operation can be set for each drug to be taken in a targeted manner; moreover, the scanned drug is compared with a contraindicated drug list, so that medicine can be effectively prevented from being taken mistakenly.

The invention relates to a home medicine management terminal, which comprises a medicine kit and one or more portable medicine boxes, wherein the medicine kit comprises a main control device for setting medicine taking information, storing medicine taking records and automatically generating a medicine taking reminding instruction; each portable medicine box comprises a portable box body; a medicine box controller which is wirelessly communicated with the main control device, controlled by the portable box body and used for uploading data to the portable box body is arranged on the portable box body; and the medicine box controller comprises a medicine box central processor, a medicine box storage device connected with the medicine body central processor, a medicine taking confirmation signal input device, a medicine taking indication device and a medicine box communication module. The home medicine management terminal is portable, and can remind a user to take medicines at any time anywhere, manually and automatically trigger to update the medicine taking records and report the medicine taking state to a medical mechanism through remote communication at any time, so that doctors can accurately master the medicine taking information of the user and adjust a medicine taking scheme timely; and the home medicine management terminal is particularly suitable for the middle-aged and aged people who are 40 to 65 years old, and suffer from chronic diseases.

The invention is applicable to the technical field of medicines, and provides a medication information management system, method and terminal equipment. The medication information management system comprises: a medication knowledge base module which includes basic information of medicines, contents of medicine components, medicine compatibility and other information, a prescription / advices of doctors audit module which is used for auditing outpatient and emergency prescriptions and advices of doctors for hospitalization according to the medication knowledge base module and the basic information, diagnosis information, allergic history information and other information of a patient, and sending the audit result to a drug dispensing system and a liquid mixing system of a pharmacy, and a medication integration module which is used for performing extraction and collection on the past medication information, medication in hospitals, medication for outpatient and discharge medication of thepatient, sorting the extracted and collected information according to the drugs, the usage and dosage and the medication course of treatment, performing medication intervention or medication guidanceon the medication situation of the patient according to the sorting result, and generating a medication instructor. Therefore, the medication information management system, method and terminal equipment can solve the problems of acquisition, utilization, processing and integration of medication information, and can realize effective beforehand intervention for medication.

The invention belongs to the technical field of medicine, and relates to a palbociclib gastric-floating tablet and a preparation method thereof. The palbociclib gastric-floating tablet comprises, by mass, 10%-30% of palbociclib, 20%-50% of hydroxypropyl methylcellulose, 20%-40% of bleaching auxiliaries, 2%-10% of foaming agents, 0%-25% of microcrystalline cellulose and 0.5%-3% of magnesium stearate. A dry granulating technology or a wet granulating technology can be used as the preparation technology. The palbociclib gastric-floating tablet is high in bioavailability, has a slow release tendency, and effectively lowers the total dosage. The palbociclib gastric-floating tablet and the preparation method thereof have the unique advantages that two different mechanisms are used for preparing the gastric-floating tablet, and accordingly the prepared tablet can keep floating in gastric juice by more than 10 hours and continuously release drugs in the hydrochloric acid solution with the pH being 1.2; the problem that the bioavailability is low due to the fact that drugs are extremely difficult to dissolve after the pH is higher than four is effectively solved; the medicine taking frequency is reduced; toxic and side effects are lightened; and the complaisance of a patient is effectively improved.

A healthcare risk index is generated using a patient or individual's pharmacy claims. The index may be used to explain and predict variation in pharmacy-related costs and variation in total healthcare costs or utilization. In particular, the index is generated by first examining the individual's pharmacy claims to identify any chronic conditions possessed by the individual. Similarly, the individual's pharmacy claims are examined to identify any compliance medications prescribed to the individual. The chronic condition information is used to generate a chronic condition score by summing regression coefficients for each chronic condition possessed by the individual. Likewise, the compliance medication information is used to generate a compliance medication score by summing products of regression coefficients for each compliance medication prescribed to the individual with associated medication supply weights. From there, a modified chronic condition score is generated by multiplying the chronic condition score by an overall chronic condition regression coefficient. The modified chronic condition score may then be further modified by subtracting a no-claims weight from the chronic condition score in cases where the individual has no pharmacy claims. Finally, the risk index may be determined by summing the modified chronic condition score and the compliance medication score.

An orally taken medicine of hyproval-PA in the form of tablet, capsule, soft capsule, instant particles, etc for treating breast cancer and functional metrorrhagia is disclosed. its advantages are high biologic utilization rate and high curative effect.

The invention relates to an oral medicinal composition formulation for treating peptic ulcer. The composition comprises esomeprazole, antiacid sodium bicarbonate and a medicinally acceptable carrier, wherein the esomeprazole contains an acid-sensitive proton pump inhibitor; and the antiacid sodium bicarbonate can improve the stability of the proton pump inhibitor. The invention also relates to a preparation method of the medicinal composition. Two active ingredients are integrated into one fixed unit formulation, so that response is quick, a medicinal scheme is simplified in the process of treating the peptic ulcer, and the compliance of a patient is improved.

The invention relates to an inhalation spray of antivirus medicines. The inhalation spray comprises the following components in percentage by mass of 0%-30% of antivirus activity agents, 0%-30% of auxiliary agents, 0%-30% of taste masking agents and the balance solvents, wherein the content of the antivirus activity agents and the content of the auxiliary agents are not 0% at the same time. Compared with the prior art, the inhalation spray disclosed by the application has the purpose that during outbreak period of epidemic corona viruses and other viruses, people do not need to occupy medicalresources in short supply and only need to inhale the antivirus medicines into respiratory tracts, medicine administration is accurately targeted, and the objective of preventing virus infection and propagation can be achieved; in addition, through united medication of the antivirus activity agents and the auxiliary agents, besides, various medicines are inhaled into the respiratory tract of a patient, synergistic treatment effects are generated, the viruses are eliminated, and serious respiratory tract and infection and serious pulmonary infection caused by the viruses can be treated; and chloroquine type antivirus medicines and macrocyclic antibiotics are inhaled through spraying for united medication, and the dosage of the medicines can be notably reduced, so that side effects of prolonged QT intervals, Tdp and sudden cardiac death caused by the medicines can be reduced.

A compound is provided, having the general structure (A): wherein A is an aryl or heteroaryl group, Y is a hydrophbic linking moiety, and L is a substitutent. The compound (A) can be used for treatment of various angiogenic-associated or hematologic disorders, such as myeloproliferative disorders in patients who do not respond to kinase-inhibition therapy that comprises administering currently used medications.

The invention relates to a tranexamic acid skin externally applied nano-preparation, as well as a preparation method and a use thereof. The nano-preparation is prepared from tranexamic acid, medicated oil, an emulsifier, pharmaceutical additives, a thickener and pure water. The tranexamic acid skin externally applied nano-preparation provided by the invention has good physiological skin compatibility and can effectively promote the percutaneous absorption of tranexamic acid, improve the effect of preventing or treating pigmentation of the tranexamic acid and avoid toxicity and side effects, which are caused by systemic administration of the tranexamic acid.

The invention provides the application of betulinic acid and salts thereof suitable for medical purpose in the preparation of a drug of a glycosidase inhibitor. The compound of the invention is the compound of lupeol type pentacyclic triterpene acid obtained by separating lagerstroemia plants. Pharmacological tests prove that the compound has obvious effect in inhibiting Alpha-glucosidase, the inhibitory activity of which exceeds acarbose 100% for initial therapy. Therefore, drug compositions made from the compound or the salts thereof suitable for medical purpose and drug excipients or carriers allowable for preparation can be applied to the preparation of drugs for preventing or treating Type II Diabetes, namely, noninsulin-dependent diabetes mellitus. The constitutional formula shown in formula (1) of the invention is shown as above.

The present invention relates to pharmaceutical compositions of various pharmaceutical actives, especially lyophilic and hydrophilic actives containing Diethylene glycol monoethyl ether or other alkyl derivatives thereof as a primary vehicle and / or to pharmaceutical compositions utilizing Diethylene glycol monoethyl ether or other alkyl derivatives thereof as a primary vehicle or as a solvent system in preparation of such pharmaceutical compositions. The pharmaceutical compositions of the present invention are safe, non-toxic, exhibits enhanced physical stability compared to conventional formulations containing such pharmaceutical actives and are suitable for use as injectables for intravenous and intramuscular administration, as well as for use as a preformed solution / liquid for filling in and preparation of capsules, tablets, nasal sprays, gargles, dermal applications, gels, topicals, liquid oral dosage forms and other dosage forms.

The invention discloses an intelligent medical online service system and an intelligent medical online service method, which solve the technical problem that in the prior art, real-time and effective tracking between doctors and patients is lacked. The intelligent medical online service system comprises a server platform, a database server, at least one portable health device, at least one doctor terminal and at least one patient terminal, wherein each doctor terminal is connected with the server platform which is also connected with the database server, each portable health device is connected with the server platform, and each patient terminal is connected with the server platform; and wherein, the portable health device is used for collecting health state data, the server platform is used for monitoring the portable health device and thereby transmitting the monitored health state data to the database server and the doctor terminal, and the server platform is used for pushing medication prompt of the doctor corresponding to the health state data to the patient terminal. Therefore, monitoring on continuous health state of the patient the medication prompt for the patient are achieved, and the medical treatment is effective, efficient and convenient.

The invention belongs to the field of medicine preparations, and relates to a pharmaceutical composition prepared by a dry granulation technology. With palbociclib or a pharmaceutical salt thereof as an effective component, proper auxiliary materials such as a filler, a disintegrant, a flow aid and a lubricant are added; and the pharmaceutical composition is prepared by tabletting or capsule filling after dry granulation. The preparation provided by the invention is designed aiming at the properties and characteristics of the palbociclib or the pharmaceutical salt thereof; the palbociclib can be rapidly released; and meanwhile, various requirements such as clinical medication, patient compliance and industrial large-scale production can be met.

The invention relates to an intelligent tumor medication instruction system. The intelligent tumor medication instruction system is characterized by comprising a patient information module, a gene mutation detection module, a medication instruction database and a detection result reporting module, wherein the patient information module is used for recording the basic information of a patient; the gene mutation detection module is used for detecting the gene mutation information of the patient, such as a gene name, a mutation site, mutation conditions, mutation frequency and germline mutation and / or somatic cell mutation; the medication instruction database is used for performing medication instruction and query according to the clinical information of the patient, automatically matching and sequencing the clinical information and the medication instruction and query results, and sending an optimum medication instruction scheme suitable for the tumor patient to the detection result reporting module; a doctor can instruct the medication on the tumor patient according to the medication scheme displayed by the detection result reporting module. The intelligent tumor medication instruction system is widely applied to the diagnosis and medication instruction process of the tumor patient.

The invention discloses a medicinal composition containing dimeticone / simethicone. The composition is mainly prepared from the following raw material medicaments in portion by weight: 1 to 1,000 portions of acetylcysteine or pharmaceutically acceptable salt thereof, and 1 to 500 portions of the dimeticone / simethicone. The composition can be prepared into various pharmaceutically acceptable preparations; and the composition can be applied to gastrointestinal endoscopy and treatment or an adjuvant drug administered before imaging examination, and compared with the acetylcysteine or the dimeticone or simethicone which is in single use at the same dosage, the composition has stronger defrothing effect, and stronger grume removal effect, so that the composition can effectively improve the visual definition of examination and treatment, reduce misdiagnosis and missed diagnosis, and improve effectiveness of diagnosis and treatment, contributes to early diagnosis discovery of digestive tract diseases, and has wide application prospect.

The invention discloses a personalized medication gene detection kit and application. The personalized medication gene detection kit is suitable for multiple kinds of sample types including dried blood spots, whole blood and buccal swabs, information of all medicine gene polymorphic sites can be acquired at once, the sequencing effective rate is 50% or above, the sequencing cover degree is 100%, the average sequencing depth exceeds 3000 X, the library building success rate is larger than or equal to 98.5%, and the medicine gene polymorphic site detection accuracy is larger than or equal to 99.9%; a primer group is high in specificity and little in nonspecific amplification, interference among primers can be well overcome, under the situation of up to 186 primer sequences, one-tube multiplePCR reaction is achieved, moreover, amplicon is high in uniformity, and under the situation of large amplification area GC content difference, overall effective amplification can be conducted. The detection kit, the primer group and a library building method can be applied to personalized medication gene detection, and guidance is provided for personalized medication.

The invention belongs to the technical field of medicine, and relates to a lurasidone hydrochloride orally-disintegrating tablet preparation and a preparation method thereof. The orally-disintegrating tablet comprises the following components in mass percent: 5-60 percent of lurasidone hydrochloride, 25-80 percent of filling material, 5-20 percent of disintegrating agent, 0.02-0.15 percent of wetting agent, 0.2-5 percent of flavoring agent and 0.5-2 percent of lubricating agent. The invention aims to provide a lurasidone hydrochloride orally-disintegrating tablet with simple preparation process, low cost, convenience in use and quick action to the indications; and compared with the conventional preparation for oral use, the lurasidone hydrochloride orally-disintegrating tablet preparation can reduce the difficulty in swallowing, improve the compliance, is suitable for special populations such as the elderly, children, patients with difficulty in swallowing and mental patients, can be fully disintegrated within 60 s, can be disintegrated into extremely fine powder, is higher in drug dissolution rate and quick in absorption, and can improve the bioavailability of insoluble drugs, for example, lurasidone hydrochloride.

A healthcare risk index is generated using a patient or individual's pharmacy claims. The index may be used to explain and predict variation in pharmacy-related costs and variation in total healthcare costs or utilization. In particular, the index is generated by first examining the individual's pharmacy claims to identify any chronic conditions possessed by the individual. Similarly, the individual's pharmacy claims are examined to identify any compliance medications prescribed to the individual. The chronic condition information is used to generate a chronic condition score by summing regression coefficients for each chronic condition possessed by the individual. Likewise, the compliance medication information is used to generate a compliance medication score by summing products of regression coefficients for each compliance medication prescribed to the individual with associated medication supply weights. From there, a modified chronic condition score is generated by multiplying the chronic condition score by an overall chronic condition regression coefficient. The modified chronic condition score may then be further modified by subtracting a no-claims weight from the chronic condition score in cases where the individual has no pharmacy claims. Finally, the risk index may be determined by summing the modified chronic condition score and the compliance medication score.

The invention relates to a dispersible tablet containing oryzanol for treating neurological system diseases and its preparing process, wherein the tablet comprises (by weight parts): oryzanol 5-200, filling agent 20-200, crumbling agent 15-40, bonding agent 1-70, flowing adjuvant or lubricating agent 0-5.

The invention discloses an oral liquid preparation for treating infantile indigestion with food retention and cough (infantile food retention removing and cough relieving oral liquid) and a preparation method thereof. In order to overcome the shortcoming of a traditional taste correcting process in the infantile food retention removing and cough relieving oral liquid, a cyclodextrin inclusion technology is adopted in the invention, and combined taste correction is carried out by utilizing other taste correcting agents; the oral liquid preparation which is suitable for pediatric medication is developed, and the industrialization of the application of the cyclodextrin inclusion technology to the production of traditional Chinese medicine oral liquid preparation is realized; the mouthfeel ofthe preparation is improved, and the medication compliance of a child is enhanced; meanwhile, the water-solubility of low-polarity effective ingredients is increased by the formation of an inclusion compound so that the quality and the stability of the preparation are enhanced.